Literature DB >> 18805914

Retesting the childhood-onset GH-deficient patient.

V Gasco1, G Corneli, G Beccuti, F Prodam, S Rovere, J Bellone, S Grottoli, G Aimaretti, E Ghigo.   

Abstract

GH deficiency (GHD) in adults has to be shown by a single provocative test, provided that it is validated. Insulin tolerance test (ITT) has been indicated as the test of choice; now also glucagon test is validated and represents an alternative. The GHRH plus arginine (ARG) test and testing with GHRH plus a GH secretagogue are equally reliable diagnostic tools, and are now considered as 'golden' standards as ITT. Childhood-onset (CO) GHD needs retesting in late adolescence or young adulthood; this is a major clinical challenge and raises questions about the most appropriate method and cut-off value. Appropriate re-evaluation of GH status is represented by simple measurement of IGF1 concentration off rhGH treatment. Clearly, low IGF1 levels are evidence of persistent severe GHD in subjects with genetic GHD or panhypopituitarism. However, normal IGF1 levels never rule out severe GHD and CO-GHD with normal IGF1 levels must undergo a provocative test. The appropriate GH cut-off limit is specific for each provocative test. As shown by the ROC curve analysis, in late adolescents and young adults, the lowest normal GH peak response to ITT is 6.1 microg/l while that to GHRH+ARG test is 19.0 microg/l. These cut-off limits, however, are just indicative as being variable as a function of the assay used. No other test is validated for retesting. As GHRH+ARG test mostly explores the GH-releasable pool, normal GH response would be verified by a second ITT in order to rule out subtle hypothalamic defect.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18805914     DOI: 10.1530/EJE-08-0293

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  9 in total

1.  Correlation between serum IGF-1 and blood lead level in short stature children and adolescent with growth hormone deficiency.

Authors:  Yan Xu; Ming-Chao Liu; Pei Wang; Bei Xu; Xin-Qin Liu; Zhi-Ping Zhang; Li-Fen Ren; Qing Qin; Yue-Yun Ma; Wen-Jing Luo; Xiao-Ke Hao
Journal:  Int J Clin Exp Med       Date:  2014-04-15

2.  Growth hormone treatment of adolescents with growth hormone deficiency (GHD) during the transition period: results of a survey among adult and paediatric endocrinologists from Italy. Endorsed by SIEDP/ISPED, AME, SIE, SIMA.

Authors:  G Aimaretti; R Attanasio; S Cannavò; M C Nicoletti; R Castello; C Di Somma; P Garofalo; L Iughetti; S Loche; M Maghnie; L Mazzanti; G Saggese; M Salerno; G Tonini; V Toscano; S Zucchini; M Cappa
Journal:  J Endocrinol Invest       Date:  2014-11-02       Impact factor: 4.256

Review 3.  Growth hormone deficiency in the transition period: body composition and gonad function.

Authors:  G Balercia; L Giovannini; F Paggi; M Spaziani; N Tahani; M Boscaro; A Lenzi; A Radicioni
Journal:  J Endocrinol Invest       Date:  2011-06-21       Impact factor: 4.256

4.  Growth Hormone Deficiency and Lysinuric Protein Intolerance: Case Report and Review of the Literature.

Authors:  Maines Evelina; Morandi Grazia; Olivieri Francesca; Camilot Marta; Cavarzere Paolo; Gaudino Rossella; Antoniazzi Franco; Bordugo Andrea
Journal:  JIMD Rep       Date:  2015-01-23

Review 5.  A review of guidelines for use of growth hormone in pediatric and transition patients.

Authors:  David M Cook; Susan R Rose
Journal:  Pituitary       Date:  2012-09       Impact factor: 3.599

6.  Approach to the Patient: Management of Pituitary Hormone Replacement Through Transition.

Authors:  Manuela Cerbone; Harshini Katugampola; Helen L Simpson; Mehul T Dattani
Journal:  J Clin Endocrinol Metab       Date:  2022-06-16       Impact factor: 6.134

Review 7.  Childhood-onset growth hormone deficiency and the transition to adulthood: current perspective.

Authors:  M Ahmid; S F Ahmed; M G Shaikh
Journal:  Ther Clin Risk Manag       Date:  2018-11-23       Impact factor: 2.423

8.  Prevalence of growth hormone (GH) deficiency in previously GH-treated young adults with Prader-Willi syndrome.

Authors:  Stephany H Donze; Layla Damen; Janiëlle A E M van Alfen-van der Velden; Gianni Bocca; Martijn J J Finken; Gera J G Hoorweg-Nijman; Petr E Jira; Mariëtte van Leeuwen; Anita C S Hokken-Koelega
Journal:  Clin Endocrinol (Oxf)       Date:  2019-04-30       Impact factor: 3.478

9.  The Challenge of Growth Hormone Deficiency Diagnosis and Treatment during the Transition from Puberty into Adulthood.

Authors:  Elena Inzaghi; Stefano Cianfarani
Journal:  Front Endocrinol (Lausanne)       Date:  2013-03-20       Impact factor: 5.555

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.